Hawaii Biotech
Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company founded in 1982, focused on developing vaccines and small molecule medical countermeasure drugs to prevent or treat infectious diseases. The company has a strong track record of securing funding from NIH and the Department of Defense, and partners with various academic, governmental, and private entities to advance its research and development efforts.
Industries
Nr. of Employees
small (1-50)
Hawaii Biotech
650 Iwilei Road, Suite 204, Honolulu, Hawaii 96817
Patents
Products
Recombinant subunit vaccine candidates for emerging infectious diseases
Recombinant protein subunit vaccine candidates developed on an insect cell expression platform targeting multiple emerging and re-emerging infectious diseases (examples include flaviviruses and alphaviruses).
Small-molecule anti-toxin drug candidates (medical countermeasures)
Small-molecule therapeutics in development to treat intoxication from biological toxins (examples stated: anthrax and botulinum neurotoxin type A).
Semi-synthetic saponin adjuvant (DMF-held)
Saponin-based semi-synthetic adjuvant suitable for parenteral and mucosal administration, maintained in an active Drug Master File and made available for third-party licensing.
Recombinant subunit vaccine candidates for emerging infectious diseases
Recombinant protein subunit vaccine candidates developed on an insect cell expression platform targeting multiple emerging and re-emerging infectious diseases (examples include flaviviruses and alphaviruses).
Small-molecule anti-toxin drug candidates (medical countermeasures)
Small-molecule therapeutics in development to treat intoxication from biological toxins (examples stated: anthrax and botulinum neurotoxin type A).
Semi-synthetic saponin adjuvant (DMF-held)
Saponin-based semi-synthetic adjuvant suitable for parenteral and mucosal administration, maintained in an active Drug Master File and made available for third-party licensing.
Services
Production of high-quality purified recombinant proteins to support internal vaccine programs and external R&D for biotech and pharmaceutical customers.
Licenseable semi-synthetic saponin adjuvant formulations with an active Drug Master File available for third-party use in parenteral and mucosal vaccine formulations.
Application of standardized platform manufacturing processes to accelerate immunogen development and facilitate tech-transfer to GMP manufacturers.
Production of high-quality purified recombinant proteins to support internal vaccine programs and external R&D for biotech and pharmaceutical customers.
Licenseable semi-synthetic saponin adjuvant formulations with an active Drug Master File available for third-party use in parenteral and mucosal vaccine formulations.
Application of standardized platform manufacturing processes to accelerate immunogen development and facilitate tech-transfer to GMP manufacturers.
Expertise Areas
- Recombinant subunit vaccine development
- Platform-based vaccine manufacturing
- Recombinant protein expression and purification
- Adjuvant formulation and DMF management
Key Technologies
- Insect cell expression (Drosophila S2) systems
- Recombinant subunit antigen design
- Protein purification and analytical release assays
- Semi-synthetic saponin-based adjuvants